Authors:
Daud, AN
Ahsan, A
Iqbal, O
Walenga, JM
Silver, PJ
Ahmad, S
Fareed, J
Citation: An. Daud et al., Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications, CL APPL T-H, 7(1), 2001, pp. 58-64
Authors:
Walenga, JM
Hoppensteadt, D
Pifarre, R
Fox, NL
Forman, S
Hunninghake, DB
Campeau, L
Herd, JA
Hoogwerf, BJ
Hickey, A
Probstfield, JL
Terrin, ML
Citation: Jm. Walenga et al., The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment, J THROMB TH, 11(2), 2001, pp. 143-149
Authors:
Kowal-Vern, A
Walenga, JM
McGill, V
Gamelli, RL
Citation: A. Kowal-vern et al., The impact of antithrombin (H) concentrate infusions on pulmonary functionin the acute phase of thermal injury, BURNS, 27(1), 2001, pp. 52-60
Authors:
Wallock, M
Jeske, WP
Bakhos, M
Walenga, JM
Citation: M. Wallock et al., Evaluation of a new point of care heparin test for cardiopulmonary bypass:the TAS heparin management test, PERFUSION-U, 16(2), 2001, pp. 147-153
Authors:
Ahmad, S
Jeske, WP
Ma, Q
Walenga, JM
Fareed, J
Citation: S. Ahmad et al., Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist, THROMB RES, 102(2), 2001, pp. 143-151
Authors:
Lewis, BE
Wallis, DE
Berkowitz, SD
Matthai, WH
Fareed, J
Walenga, JM
Bartholomew, J
Sham, R
Lerner, RG
Zeigler, ZR
Rustagi, PK
Jang, IK
Rifkin, SD
Moran, J
Hursting, MJ
Kelton, JG
Citation: Be. Lewis et al., Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia, CIRCULATION, 103(14), 2001, pp. 1838-1843
Authors:
Amin, HM
Ahmad, S
Walenga, JM
Hoppensteadt, DA
Leitz, H
Fareed, J
Citation: Hm. Amin et al., Soluble P-selectin in human plasma: Effect of anticoagulant matrix and itslevels in patients with cardiovascular disorders, CL APPL T-H, 6(2), 2000, pp. 71-76
Authors:
Wallis, DE
Lewis, BE
Messmore, HL
Pifarre, R
Walenga, JM
Citation: De. Wallis et al., Inadequacy of current prevention strategies for heparin-induced thrombocytopenia (vol 5, pg S16, 1999), CL APPL T-H, 6(2), 2000, pp. 114-114
Authors:
Koval-Vern, A
McGill, V
Walenga, JM
Gamelli, RL
Citation: A. Koval-vern et al., Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries, J BURN CARE, 21(2), 2000, pp. 115-127
Authors:
Scazziota, A
Altman, R
Rouvier, J
Gonzalez, C
Ahmed, Z
Jeske, WP
Walenga, JM
Fareed, J
Citation: A. Scazziota et al., Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression, THROMB RES, 100(6), 2000, pp. 479-488
Authors:
Yu, GL
LeBrun, L
Gunay, NS
Hoppensteadt, D
Walenga, JM
Fareed, J
Linhardt, RJ
Citation: Gl. Yu et al., Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site, THROMB RES, 100(6), 2000, pp. 549-556
Authors:
Ahmad, S
Jeske, WP
Walenga, JM
Aldabbagh, A
Iqbal, O
Fareed, J
Citation: S. Ahmad et al., Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: Towards the development of a HIT model in primates, THROMB RES, 100(1), 2000, pp. 47-54
Authors:
Amiral, J
Pouplard, C
Vissac, AM
Walenga, JM
Jeske, W
Gruel, Y
Citation: J. Amiral et al., Affinity purification of heparin-dependent antibodies to platelet factor 4developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation, BR J HAEM, 109(2), 2000, pp. 336-341
Authors:
Fabris, F
Ahmad, S
Cella, G
Jeske, WP
Walenga, JM
Fareed, J
Citation: F. Fabris et al., Pathophysiology of heparin-induced thrombocytopenia clinical and diagnostic implications - A review, ARCH PATH L, 124(11), 2000, pp. 1657-1666
Authors:
Jeske, W
Hoppensteadt, DA
Pifarre, R
Walenga, JM
Fareed, J
Citation: W. Jeske et al., Mechanism of blood coagulation. Newer aspects of anticoagulant and antithrombotic therapy, ACUTE PULMONARY EMBOLISM, 2000, pp. 95-122
Authors:
Ahmad, S
Ahsan, A
George, M
Iqbal, O
Jeske, WP
McKenna, R
Lewis, BE
Walenga, JM
Fareed, J
Citation: S. Ahmad et al., Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications, CL APPL T-H, 5(4), 1999, pp. 252-258